Top Page
Noxopharm Ltd.
(Sydney:NOX)
Noxopharm Ltd. (NOX) vs. iShares MSCI Australia ETF (EWA)
Noxopharm Ltd. Business Overview & Revenue Model
Noxopharm Ltd. Financial Statement Overview
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.82M | 2.40M | 6.01M | 5.43M | 5.61M |
| Gross Profit | -1.45M | -534.81K | 5.86M | 5.17M | 5.35M |
| EBITDA | -5.38M | -5.95M | -20.85M | -23.70M | -5.85M |
| Net Income | -4.88M | -3.58M | -15.06M | -18.67M | -9.35M |
Balance Sheet | |||||
| Total Assets | 4.58M | 6.78M | 10.13M | 26.59M | 47.85M |
| Cash, Cash Equivalents and Short-Term Investments | 1.55M | 2.32M | 3.01M | 14.01M | 26.80M |
| Total Debt | 2.48M | 0.00 | 0.00 | 160.62K | 349.31K |
| Total Liabilities | 3.89M | 1.29M | 1.06M | 2.48M | 7.08M |
| Stockholders Equity | 689.96K | 5.50M | 9.07M | 24.12M | 40.78M |
Cash Flow | |||||
| Free Cash Flow | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Operating Cash Flow | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Investing Cash Flow | 2.48M | 0.00 | 123.51K | 0.00 | 225.23K |
| Financing Cash Flow | 2.60M | 0.00 | -178.09K | 975.73K | 28.32M |
Noxopharm Ltd. Technical Analysis
Noxopharm Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$59.04M | 20.47 | 27.24% | 2.81% | 0.65% | -9.90% | |
52 Neutral | AU$94.16M | -11.14 | -47.98% | ― | 700.00% | 26.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$66.25M | -6.30 | -49.72% | ― | ― | 10.78% | |
45 Neutral | AU$8.84M | ― | -469.35% | ― | ― | 46.28% | |
43 Neutral | AU$20.89M | -3.62 | -157.93% | ― | ― | -36.89% | |
41 Neutral | AU$130.13M | -3.95 | ― | ― | ― | 0.66% |
Noxopharm Ltd. Corporate Events
Noxopharm Limited reported a sharp widening of its half-year loss to $1.84 million for the period ended 31 December 2025, a 49% increase from the prior corresponding period’s $1.24 million loss. The company’s net tangible assets per share fell into negative territory at minus 0.39 cents from 0.24 cents, and no dividends were paid or declared, underscoring ongoing funding needs and the capital-intensive nature of its development-stage operations.
The absence of dividends for both the current and previous half-year periods highlights Noxopharm’s continued focus on reinvesting resources into its pipeline rather than returning capital to shareholders. With no changes in control, associates or joint ventures reported, the results primarily reflect internal cost structures and investment in R&D, leaving investors focused on the company’s ability to translate its spending into future clinical and commercial milestones.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm Limited has issued 15 million fully paid ordinary shares at an issue price of zero dollars per share under a financing facility announced on 27 February 2026, expanding its capital base without providing a disclosure document to investors. The company stated it remains compliant with its financial reporting and continuous disclosure obligations under the Corporations Act and confirmed there is no excluded information that would affect the market, underscoring regulatory transparency around the new share issuance.
The notice clarifies that the share issue was conducted in accordance with section 708A(5)(e) of the Corporations Act, which allows certain placements without a prospectus, potentially streamlining Noxopharm’s access to funding to support its development programs. While the issue price of zero implies the shares were issued as part of an existing financing arrangement rather than a conventional capital raising, it nonetheless alters the company’s share structure and may have implications for existing shareholders in terms of dilution and future funding flexibility.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm Ltd has applied for quotation on the ASX of 15 million new ordinary fully paid shares issued on 27 February 2026. The shares were created in connection with a new financing facility, with the share issue and execution of the related facility agreement completed on the same day, indicating the company is bolstering its funding capacity through equity-linked arrangements.
The additional securities expand Noxopharm’s quoted share base and provide access to capital that can be deployed into its ongoing operations and development programs. This move may dilute existing shareholders but is likely aimed at strengthening the company’s financial position and supporting its strategic and research activities in the biopharmaceutical market.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm has received a $2.8 million rebate under the Australian Government’s R&D Tax Incentive scheme for FY2025, bolstering its cash reserves as it advances its Sofra technology platform and HERACLES clinical program. The funding supports preparation for next-phase clinical trials, expanded external collaborations and further development of Sofra-based drug candidates, including SOF-SKN for cutaneous lupus, which targets a global market exceeding US$3.3 billion amid broader growth in autoimmune and immuno-oncology therapeutics.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm Limited has entered into an At-the-Market Subscription Agreement with Acuity Capital, securing access to up to $5 million in standby equity capital over a five-year period to July 2031. The facility gives the company full discretion over whether to draw on the funding, the number of shares issued, pricing floors and timing, and can be terminated at any time without penalty, while placing no restrictions on alternative capital-raising avenues.
As security for the arrangement, Noxopharm will place 15 million fully paid ordinary shares from its existing capacity with Acuity Capital at nil cash consideration, with the option to buy back and cancel these shares at no cost upon early termination or maturity, subject to shareholder approval. The flexible structure is designed to provide additional balance sheet support and financial agility as the company advances its Sofra and Chroma platform-based drug development programs in the competitive cancer and autoimmune therapeutics space.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm has announced that the breakthrough science underpinning its Sofra platform has been published in Nature Immunology, a leading peer-reviewed journal in the field. The paper, led by Professor Michael Gantier of the Hudson Institute with contributions from Noxopharm staff and international collaborators, details a newly discovered anti-inflammatory mechanism that protects against autoimmune disorders.
The research explains how specific RNA fragments can modulate immune sensors TLR7 and TLR8, enabling the development of novel therapeutics such as Noxopharm’s SOF-SKN candidate for autoimmune skin conditions. Endorsement from prominent U.S. oligonucleotide expert Professor Arthur Krieg and the journal’s prestige bolster the scientific credibility of Sofra, potentially enhancing Noxopharm’s industry profile and attracting greater interest from partners and investors as it advances its drug pipeline for diseases like lupus, psoriasis, diabetes and rheumatoid arthritis.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm reported a strong December quarter, highlighted by the successful completion of dosing in all cohorts of its milestone HERACLES clinical trial evaluating SOF-SKN™, which delivered highly positive safety and tolerability results and clears a key regulatory hurdle ahead of planned Phase II-enabling studies. The company also broadened the potential applications of its Sofra platform through a new Material Transfer Agreement with an overseas partner developing an innovative drug-delivery system for inflammatory bowel disease, secured its first US “first-tier” composition of matter patent protecting its immune-modulatory oligonucleotides for cancer treatment, and received high-profile recognition from the Victorian Government and the scientific community, reinforcing its positioning at the cutting edge of RNA technology and bolstering the platform’s credibility with investors and collaborators.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm has successfully completed the clinical component of its HERACLES trial, reporting that the second and final multiple-dose cohort of its topical drug candidate SOF-SKN was safe and well tolerated across all dosing groups. The positive safety profile, combined with strong participant compliance and rapid trial progression, clears the way for Phase II-enabling studies and drug scale-up, advancing SOF-SKN’s development for cutaneous lupus erythematosus and potentially other autoimmune-related skin diseases. The outcome strengthens Noxopharm’s position in the competitive autoimmune market and supports broader commercial prospects for its Sofra platform, which targets a range of immune-related conditions with significant global market potential.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm has issued 2.6 million new convertible notes with a face value of $1 each and 520,000 unlisted options to sophisticated and professional investors, rolling over an equivalent value of maturing notes first issued in January 2025. The notes, which carry 12% annual interest and mature in January 2027, can convert into between about 29.4 million and 41.6 million shares depending on the conversion price, while the attached options carry a separate exercise price; together, these securities will increase the number of instruments on issue and, upon conversion or exercise, dilute existing shareholders, although the transaction does not bring in fresh cash but instead extends the company’s existing convertible funding structure.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm Limited has notified the market of the issue of 520,000 unquoted options, exercisable at A$0.1488 and expiring on 10 September 2027, along with 2.6 million unquoted convertible notes, both dated 2 January 2026. The new options and convertible notes expand the company’s pool of unquoted securities and indicate continued use of structured equity and hybrid instruments to support its financing needs, with potential future dilution and capital structure changes relevant to existing shareholders and investors tracking the company’s funding strategy.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm Limited has notified the market that 2.6 million NOXAH convertible notes have ceased following repayment or redemption without conversion, effective 2 January 2026. The cessation of these convertible debt securities indicates a reduction in the company’s outstanding convertible obligations, which may simplify its capital structure and marginally lessen potential future equity dilution for existing shareholders.
The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.
Noxopharm Ltd. has announced a change in the director’s interest, specifically involving Fred Bart, who has acquired 250,000 options and 1,250,000 convertible notes through 4F Investment Pty Limited. This change was approved by shareholders on November 18, 2025, and reflects a strategic move to enhance the company’s financial instruments, potentially impacting its market positioning and shareholder value.
Noxopharm Limited has issued 1,250,000 convertible notes and 250,000 unlisted options to 4F Investments Pty Limited, associated with a company director. This financial maneuver, involving a conversion of an unsecured loan into convertible notes, will not bring new cash inflow but will impact the company’s capital structure by potentially increasing the number of shares if the notes are converted. The move is designed to allow the resale of shares without disclosure to retail investors, potentially diluting existing shareholdings and altering the company’s equity distribution.
Noxopharm Ltd. has announced the issuance of unquoted equity securities, including 250,000 options expiring in 2027 and 1,250,000 convertible notes. This move is part of the company’s financial strategy to support its ongoing operations and growth in the oncology sector, potentially impacting its market position and stakeholder interests.